Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Jan 1.

Published in final edited form as: Am J Hematol. 2013 Nov 20;89(1):68–73. doi: 10.1002/ajh.23590

Table 1.

Characteristics of patients and controls. Data are expressed as number or mean (range).

		Controls	ET	ET
		Controls	ET	JAK2V617F negative	JAK2V617F positive
Number		71	73	34	39
Sex (M/F)		33/38	27/46	16/18	13/26
Age (years)		47 (26-70)	57 (23-81)^*	54 (23-77)	60 (35-81)§
Platelets (x10^9/L)		249 (158-450)	604 (223-1451)^*	666 (223-1451)	556 (239-1427)
WBC (x10^9/L)		6.4 (3.7-10.3)	7.4 (3.2-13.3)	7.2 (3.2-11.7)	7.54 (5.1-13.3)
RBC (x10^6/L)		4.8 (3.6-5.5)	4.5 (3.0-6.6)	4.4 (3.2-5.6)	4.5 (3.0-6.6)
HCT (%)		42 (35-48)	41 (33-48)	40 (33-46)	41 (34-48)
THERAPY	NT	-	11	4	7
	ASA	-	29	18	11
	HU	-	5	3	2
	HU+ASA	-	28	9	19
THROMBOSIS (arterial/venous)		-	26 (18/8)	6 (6/3)	20 (15/5)^§

^*

indicates p value < 0.05. ET essential thrombocythemia. WBC= White Blood Cell count; NT= not treated; ASA= Aspirin; HU= Hydroxyurea.